The Rubella Vaccine Market Is Predicted To Reach USD XX Million With A CAGR Of XX% According To Market Data Forecast Report

The Rubella Vaccine Market Is Predicted To Reach USD XX Million With A CAGR Of XX% According To Market Data Forecast Report

ID: 6409 | April 2018 | Region: Global


The Rubella Vaccine Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Rubella Vaccine Market is estimated to be USD XX million in 2018 and predicted to rise to USD XX million by 2023 with a CAGR of XX%. The market is segmented by End User (Pediatric Rubella Vaccine, Adult Rubella Vaccine, and Traveler Rubella Vaccine). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.

The major factors that fuel the growth of the market are an increase in the incidence of rubella infection globally Approximately 100,000 infants are affected by rubella annually, thus increasing the government focus on rubella vaccination, which further propels the market growth. However, inherent disadvantages of using human diploid cell technology for constructing rubella vaccines such as high selectivity and insufficient yield, restrain the growth of the market. Conversely, ongoing R&D activities for the advancement of rubella vaccines are expected to offer lucrative opportunities for the growth of the market.

The global Rubella Vaccine market is segmented on the basis of End User. On the basis of End User, the market is segmented into Pediatric Rubella Vaccine, Adult Rubella Vaccine, and Traveler Rubella Vaccine.

On the basis of geography, the Rubella Vaccine market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the Rubella Vaccine market followed by Europe and Asia Pacific.  Asia Pacific is expected to witness the highest CAGR in the coming years.

The market is dominated by companies like Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).

Browse through the full report at “https://www.marketdataforecast.com/market-reports/rubella-vaccine-market-6397/” and checkout our recent reports in the Biotechonogly category at “https://www.marketdataforecast.com/subcategory/biotechnology-3/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.